FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, specifically GLP-1/glucagon receptor peptide agonists, and can be used in medicine for the treatment of obesity. Peptides with the general structure HX2QGTFTSDX10SX12X13LX15X16X17X18AX20X21FX23X24WLX27X28GX30 (SEQ ID NO:4), as well as their modified forms, for example HSQGTFTSDK(gE-palmitoyl)SEYLDSERARDFVAWLEAGG.
EFFECT: invention provides effective reduce of body weight, that can be used in the treatment of obesity.
4 cl, 8 dwg, 17 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY | 2011 |
|
RU2604067C2 |
| GLUCAGON ANALOGUES, POSSESSING HIGHER SOLUBILITY AND STABILITY IN BUFFERS WITH PHYSIOLOGICAL Ph VALUES | 2009 |
|
RU2560254C2 |
| GLUCAGON ANALOGUES, HAVING HIGH SOLUBILITY IN PHYSIOLOGICAL pH BUFFERS | 2008 |
|
RU2477286C2 |
| PRODRUGS CONTAINING HYALURONIC ACID CONJUGATE, LINKER AND DOUBLE AGONIST GLP-1/GLUCAGON | 2016 |
|
RU2719482C2 |
| GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS | 2008 |
|
RU2432361C2 |
| INSULIN-INCRETIN CONJUGATES | 2014 |
|
RU2678134C2 |
| POLYPEPTIDES SELECTIVE TO GLUCAGON RECEPTORS AND THEIR APPLICATION METHODS | 2017 |
|
RU2760007C2 |
| DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | 2013 |
|
RU2652783C2 |
| AMIDE-BASED PRODRUGS OF GLUCAGON SUPERFAMILY PEPTIDES | 2009 |
|
RU2550696C2 |
| OXYINTOMODULINE | 2009 |
|
RU2542362C2 |
